drugset

drugset / Trial / NCT05493995

A Study of Penpulimab and Anlotinib Plus Nab-paclitaxel and Gemcitabine for Metastatic Pancreatic Cancer.

NCT05493995 ↗

Phase 2 Completed 66 enrolled The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · collab

NaSingle-groupOpen-labelTreatment

Summary

It is a trial to assess the efficacy and safety of Penpulimab and Anlotinib in Combination With Nab-paclitaxel Plus Gemcitabine as first-line Therapy in Patients (Pts) With Metastatic Pancreatic Cancer.

Timeline

Start: 2022-07-21
Primary completion: 2024-05-01
Completion: 2024-05-01

Publications

Sha H, Tong F, Ni J, Sun Y, Zhu Y, Qi L, Li X, Li W, Yang Y, Gu Q, Zhang X, Wang X, Zhu C, Chen D, Liu B, Du J. First-line penpulimab (an anti-PD1 antibody) and anlotinib (an angiogenesis inhibitor) with nab-paclitaxel/gemcitabine (PAAG) in metastatic pancreatic cancer: a prospective, multicentre, biomolecular exploratory, phase II trial. Signal Transduct Target Ther. 2024 Jun 7;9(1):143. doi: 10.1038/s41392-024-01857-6.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Catequentinib	Small molecule	12 mg	Oral
Subject	Gemcitabine	Small molecule	1 g	Intravenous
Subject	Paclitaxel	Small molecule	125 mg/m2	Intravenous
Subject	Penpulimab	Monoclonal antibody	200 mg	Intravenous

Indications